Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
Renal dysfunction and urinary abnormalities, which are usually related to drug toxicity, secondary amyloidosis, or those which overlap with other autoimmune conditions, are frequently observed in patients with rheumatoid arthritis. This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac. The present case suggests that any kind of non-steroidal anti-inflammatory drug can cause membranous nephropathy; thus, physicians should be aware of this renal toxicity when prescribing these drugs.
Sugimoto
Toshiro
T
Department of Internal Medicine, Shiga University of Medical Science, Otsu. toshiro@belle.shiga-med.ac.jp
Aoyama
Masahiro
M
Kikuchi
Katsuhisa
K
Sakaguchi
Masayoshi
M
Deji
Naoko
N
Uzu
Takashi
T
Nishio
Yoshihiko
Y
Kashiwagi
Atsunori
A
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D001707:Biopsy, Needle; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D017308:Etodolac / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015433:Glomerulonephritis, Membranous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007677:Kidney Function Tests; D008875:Middle Aged; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D052246:Cyclooxygenase 2 Inhibitors; D017308:Etodolac